# FDA again turns back Capricor Duchenne cell therapy

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/capricor-fda-duchenne-cell-therapy-deramiocel/875384/) · 2026-11-21 · Medicine
Page: https://themorning.science/story/fda-again-turns-back-capricor-duchenne-cell-therapy-43e4e6bbe3b0d0ef
Kind: other · Impact: medium

## In brief

- The FDA again rejected Capricor's Duchenne cell therapy, deramiocel.
- In an unusual statement, the FDA accused Capricor of "serious data integrity violations" that compromised its study findings.
- This is the second rejection of deramiocel since 2025.

## Why it matters

The case shows that regulators can reject a therapy over data integrity problems that undermine a study's findings, so the reliability of trial data is decisive for approval.

## Timeline

- 2026-11-21: FDA publicly accuses Capricor of serious data integrity violations and rejects deramiocel for the second time

## Coverage

- [FDA again turns back Capricor Duchenne cell therapy](https://www.biopharmadive.com/news/capricor-fda-duchenne-cell-therapy-deramiocel/875384/) — BioPharma Dive - Latest News, 2026-11-21

Tags: duchenne, cell therapy, fda, data integrity, clinical trials, drug regulation

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
